BioSpace News Archive

New Cooperative Agreement to Aid in the Development of Therapeutics and Vaccines, Improve Access to Medication [13-January-2022] ROCKVILLE, Md. , Jan. 13, 2022 /PRNewswire/ -- The Institute for Bioscience and Biotechnology Research (IBBR) announces a newly funded five-year cooperative agreement with the National Institute of Standards and Technology (NIST) headed by t

Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) announced today that, in connection with its previously announced intention to separate its eye health business, its wholly owned subsidiary, Bausch + Lomb Corporation (“Bausch + Lomb”), has publicly filed a Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission.

dievini and the Federal Republic of Germany announced the signing of a supplement to the shareholders’ agreement between Kreditanstalt für Wiederaufbau and the investment company dievini Hopp BioTech holding GmbH & Co. KG, DH-LT-Investments GmbH, and Dietmar Hopp related to their common shares in CureVac N.V.

Castle Biosciences, Inc. (Nasdaq: CSTL), a leader in transforming disease management and improving patient outcomes through innovative diagnostics, today announced the publication of clinical performance study data demonstrating that DecisionDx®-SCC provides significant and independent prognostic value for stratifying metastasis risk in patients with cutaneous squamous cell carcinoma (SCC) with one or more risk factors (high risk).

The Supreme Court of the United States today issued a temporary stay blocking the Biden administration’s federal vaccine mandate for employers with over 100 employees.

Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that its partner in China, Angel Pharmaceuticals Ltd. (Angel Pharma), has treated the first patient in its Phase 1/1b clinical trial of Corvus’ small molecule ITK inhibitor CPI-818 for the treatment of relapsed/refractory T-cell lymphomas (TCL) in China.

Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), and Singapore’s Experimental Drug Development Centre (“EDDC”) today announced a global licensing agreement under which Everest will obtain exclusive worldwide rights to develop, manufacture and commercialize EDDC’s series of viral 3C-like (“3CL”) protease inhibitors as potentially best-in-class COVID-19 oral antiviral treatments.

Transparency Market Research has published a new report on the surgical microscopes market.

Surgical information systems entail leveraging a host of software solutions that cater exclusively to the needs of the perioperative process.

The mutation detection kits in the genome editing market have been estimated to experience various growth opportunities in the years to come.